Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report.

导出 OA

翻译打印收藏纠错

作者： Jie,Li ^[1] ; Tengfei,Gu ^[1] ; Shengping,Hu ^[1] ; Liang,Wang ^[2] ; Ting,Chen ^[1]

作者单位： Department of Urology, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China. ^[1] Medical Affairs Department, Guangzhou Gloria Biosciences Co. Ltd., Beijing, China. ^[2]

主题词男(雄)性(Male);人类(Humans);中年人(Middle Aged);前列腺肿瘤(Prostatic Neoplasms);雄激素拮抗药(Androgen Antagonists);雄激素类(Androgens);前列腺特异抗原(Prostate-Specific Antigen);前列腺切除术(Prostatectomy)

DOI 10.1097/MD.0000000000032870

PMID 36820603

发布时间 2023-03-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Medicine

2023年102卷6期

e32870页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report.

Medicine

相似文献

Medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Personalized downstaging treatment with ADT, chemotherapy and add-on zimberelimab for very-high-risk clinically localized prostate cancer: A case report.

Medicine

相似文献

Medicine

相关期刊

检索历史清除